Project Grant R01CA291546
Award Date
3/1/25
Completion Date
2/28/30
Dollars Obligated
$343K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award of $470,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) will support a 5-year research program led by the Institute for Cancer Research to characterize the molecular interactions that couple the repair of oxidative DNA damage and gene regulation at G-quadruplex DNA structures. The research aims to elucidate the role of the base excision repair protein APE1 in this process and...
This $514,582 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research at the University of North Carolina at Chapel Hill (UNC-CH) to investigate the role of the APOBEC3 enzyme in bladder cancer initiation, progression, and treatment resistance. Key objectives include: Determining how APOBEC3 promotes squamous differentiation in bladder tumors and its association with chemotherapy resistance. Analyzing the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) totaling $106,249 will support research at the University of North Carolina at Chapel Hill on the mutagenic effects of the APOBEC3A and APOBEC3B enzymes in urothelial (bladder) carcinoma. The research aims to determine if these enzymes differentially drive APOBEC-induced mutagenesis, promote intratumoral heterogeneity, and influence response to anti-PD-1 immune checkpoint blockade...
This $238,890 federal Project Grant award, issued by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, supports research conducted by Duke University to explore the relationship between chromosomal instability, loss of chromosome 17p, and sensitivity to inhibition of the mitotic regulator NDE1 in cancer cells. The key objectives of the research are to define the relationship between NDE1 dependence, 17p loss, and chromosomal instability, characterize the...
The federal Project Grant award of $1,915,018, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to determine the structural and molecular basis by which the RAD51 paralog complexes CX3 and BCDX2 promote RAD51-dependent homologous recombination (HR) and how their dysregulation leads to cancer. The multi-PI research team will use single particle cryo-EM, single-molecule DNA curtain assays, and other biochemical...
The National Cancer Institute (NCI) awarded a $393,943 project grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Washington University to support research aimed at understanding and targeting base damage repair mechanisms in BRCA-mutant cancers. The research project seeks to define the cellular and biochemical mechanisms by which loss of the chromatin remodeling enzyme ALC1 can enhance the sensitivity of BRCA-mutant cancer cells to PARP inhibitor therapies. This...
This $303,842 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to define the impact of APOBEC3A deaminase activity on replication fork progression and the mechanism by which the SMC5/6 complex protects replication forks from this deaminase activity. The goals of the 5-year project are to: 1) identify the cellular mechanisms that enable replication forks to tolerate obstacles...
The National Cancer Institute (NCI) awarded a $487,393 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research in New York. The grant funding will support research to determine the role of key proteins involved in backup DNA double-strand break repair pathways, such as RAD52, HELQ, and POLQ, in homologous recombination deficient (HRD) cancers. The research aims to discover additional proteins engaged in these...
This is a Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), to the University of Pittsburgh. The $642,394 grant, awarded on April 3, 2025, supports research investigating the impact of deoxyuridine (DU) contamination in DNA on innate immune responses. The project aims to identify pattern recognition receptors that do not recognize DU-rich DNA fragments, determine how DU disrupts RNA polymerase III-dependent...
This Project Grant award of $408,913 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research at the University of California, Irvine aimed at understanding the mechanisms of cell competition in fruit flies. The research investigates how genes encoding ribosomal proteins can act as sensors to detect and eliminate aneuploid cells with abnormal chromosome counts, which is a hallmark of aging and cancer. The project will...